Longwood Fund
Overview
Longwood Fund is a venture capital firm dedicated to creating and investing in novel healthcare companies that develop important treatments to help patients while generating significant value for investors . The Longwood team has a long history of successfully launching and building important life science companies while providing operational leadership and strategic guidance . Collectively, the Partners at Longwood Fund have co-founded approximately 25 companies with over 20 launched or marketed drugs and therapies, as well as over two dozen clinical-stage assets, all focused on helping patients in need .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Coultreon Biopharma | Apr 2026 | Series A | Co-investor |
| Neomorph | Apr 2026 | Series B | Co-investor |
| Sidewinder | Apr 2026 | Series B | Co-investor |
| Sidewinder Therapeutics | Apr 2026 | Series B | Co-investor |
| Mediar Therapeutics | Jan 2026 | Series B | Co-investor |
Key People
John McCabe
Operating Partner
Rob Hadfield
General Counsel And Operating Partner
Annalisa D'Andrea
Venture Partner
Lea Hachigian
Venture Partner
Rich Aldrich
Venture Partner
Roger Tung
Venture Partner
Vikas Goyal
Venture Partner, Growth Investments
Aleks Radovic-Moreno
Partner
David Donabedian
Executive Partner
Lizzie Ngo
Principal
Lucy Liu
Principal
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
